JTCS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Belkin, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Belkin, M.

J Thorac Cardiovasc Surg 2009;138:1257-1261
© 2009 The American Association for Thoracic Surgery


Meeting Proceedings

Highlights of the 2009 Society of Vascular Surgery annual meeting

Michael Belkin, MD*

Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass

* Address for reprints: Michael Belkin, MD, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. (Email: mbelkin@partners.org).

The first 300 words of the full text of this article appear below.


    Introduction
 
The annual meeting for the Society of Vascular Surgery (SVS) took place June 11 to 14, 2009, in Denver, Colorado. A highlight of the meeting was the presidential address of G. Patrick Clagett, who raised the question: "Does Vascular Surgery Cost Too Much?" He reviewed the staggering cost of healthcare in our country and stressed that the rate of growth in healthcare expenditures is not sustainable and that the huge disparity in healthcare spending among a variety of industrialized nations has not translated into better healthcare outcomes. Dr Clagett described the unusual paradox that higher healthcare spending has often been associated with lower quality of care and slightly worse outcomes. He went on to say that a significant proportion of President Obama's $1.1 billion economic stimulus package has gone to the National Institutes of Health, Agency for Healthcare Research and Quality, and Department of Health and Human Services, specifically for comparative effectiveness research (CER). Although not specifically stated, CER will have clear economic implications, and it is hoped that these programs will reduce variation in practice and save money. Dr Clagett stressed that the SVS has been active in CER through its Practice Guidelines and Reporting Standards Committees. The SVS Vascular Registry has also been an important contribution. Finally, Dr Clagett charged the members of the SVS to be more actively involved in CER. He cited that of all specialty groups managing peripheral vascular disease, we are the most unbiased because we are able to offer all treatment modalities, and are thus best positioned to offer high-quality CER. He concluded by stating, "Finally, these mandates are clearly spelled out in our mission statement. Integrity is our middle name. This is the right thing to do for our membership, for our patients, and for the public."

K. Wayne Johnston, MD, from . . . [Full Text of this Article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The American Association for Thoracic Surgery.